Rein Therapeutics (RNTX) Competitors $1.67 -0.26 (-13.47%) As of 03/25/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock RNTX vs. IKT, LRMR, ACRV, CYBN, ADCT, IVA, CCCC, SCPH, GLSI, and HURAShould you be buying Rein Therapeutics stock or one of its competitors? The main competitors of Rein Therapeutics include Inhibikase Therapeutics (IKT), Larimar Therapeutics (LRMR), Acrivon Therapeutics (ACRV), Cybin (CYBN), ADC Therapeutics (ADCT), Inventiva (IVA), C4 Therapeutics (CCCC), scPharmaceuticals (SCPH), Greenwich LifeSciences (GLSI), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry. Rein Therapeutics vs. Inhibikase Therapeutics Larimar Therapeutics Acrivon Therapeutics Cybin ADC Therapeutics Inventiva C4 Therapeutics scPharmaceuticals Greenwich LifeSciences TuHURA Biosciences Rein Therapeutics (NASDAQ:RNTX) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends, community ranking and profitability. Which has more volatility and risk, RNTX or IKT? Rein Therapeutics has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Does the MarketBeat Community believe in RNTX or IKT? Inhibikase Therapeutics received 9 more outperform votes than Rein Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformRein TherapeuticsN/AN/AInhibikase TherapeuticsOutperform Votes981.82% Underperform Votes218.18% Do analysts rate RNTX or IKT? Inhibikase Therapeutics has a consensus target price of $6.50, suggesting a potential upside of 174.26%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Rein Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rein Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is RNTX or IKT more profitable? Rein Therapeutics' return on equity of -74.08% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rein TherapeuticsN/A -74.08% -27.93% Inhibikase Therapeutics N/A -350.63%-201.82% Which has higher valuation & earnings, RNTX or IKT? Rein Therapeutics has higher earnings, but lower revenue than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRein TherapeuticsN/AN/A-$15.73M-$3.12-0.54Inhibikase Therapeutics$260K632.26-$19.03M-$2.67-0.89 Does the media favor RNTX or IKT? In the previous week, Rein Therapeutics had 2 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 2 mentions for Rein Therapeutics and 0 mentions for Inhibikase Therapeutics. Rein Therapeutics' average media sentiment score of 0.00 equaled Inhibikase Therapeutics'average media sentiment score. Company Overall Sentiment Rein Therapeutics Neutral Inhibikase Therapeutics Neutral Do institutionals and insiders believe in RNTX or IKT? 90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 5.1% of Rein Therapeutics shares are held by company insiders. Comparatively, 4.6% of Inhibikase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryRein Therapeutics beats Inhibikase Therapeutics on 8 of the 14 factors compared between the two stocks. Remove Ads Get Rein Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNTX vs. The Competition Export to ExcelMetricRein TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.18M$6.99B$5.68B$8.32BDividend YieldN/A2.72%4.55%4.02%P/E Ratio-0.547.2324.5519.25Price / SalesN/A230.77395.7294.09Price / CashN/A65.6738.1634.64Price / Book1.186.617.064.46Net Income-$15.73M$142.13M$3.19B$247.07M7 Day Performance-10.70%2.79%1.49%3.05%1 Month Performance-23.04%2.70%5.87%-2.85%1 Year PerformanceN/A-4.42%14.94%4.63% Rein Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNTXRein TherapeuticsN/A$1.67-13.5%N/AN/A$36.18MN/A-0.549News CoverageGap UpIKTInhibikase Therapeutics0.9792 of 5 stars$2.37-2.1%$6.50+174.3%+7.2%$164.39M$260,000.00-0.896LRMRLarimar Therapeutics2.3636 of 5 stars$2.54+1.2%$20.13+692.3%-69.5%$162.07MN/A-2.2130Earnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageACRVAcrivon Therapeutics2.0883 of 5 stars$5.36+4.3%$23.67+341.5%-13.8%$160.04MN/A-1.9958Upcoming EarningsCYBNCybin2.7879 of 5 stars$7.31-0.8%$86.00+1,076.5%N/A$157.00MN/A-1.6750ADCTADC Therapeutics1.6927 of 5 stars$1.61-5.6%$8.50+429.6%-61.6%$155.19M$70.72M-0.67310IVAInventiva1.4736 of 5 stars$2.88-2.0%$12.60+337.5%-27.8%$151.13M$15.62M0.00100Upcoming EarningsNews CoverageCCCCC4 Therapeutics1.7476 of 5 stars$2.12-3.2%$12.50+489.6%-73.4%$150.50M$35.58M-1.25150SCPHscPharmaceuticals3.5874 of 5 stars$3.00-0.3%$14.00+366.7%-38.3%$150.12M$30.28M-1.5830Earnings ReportGLSIGreenwich LifeSciences1.6316 of 5 stars$11.11-2.0%$38.00+242.0%-45.2%$146.04MN/A-13.893HURATuHURA BiosciencesN/A$3.33-16.8%$13.00+290.4%N/A$140.81MN/A0.00N/AUpcoming Earnings Remove Ads Related Companies and Tools Related Companies IKT Competitors LRMR Competitors ACRV Competitors CYBN Competitors ADCT Competitors IVA Competitors CCCC Competitors SCPH Competitors GLSI Competitors HURA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNTX) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rein Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rein Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RNTX Stock Free RNTX Stock Alerts